Medxy AI – Page 171

From Discovery to Breakthroughs: How Multiple Myeloma Survival Has Doubled in 20 Years

By MedXY 10/24/2025

Over the past two decades, advances in therapy have doubled the median survival of multiple myeloma patients, transforming this once devastating cancer into a more manageable disease through targeted drugs and immune therapies.

Oncology Urology

Breakthrough ADC-Based Combination Therapy Achieves Over 95% Disease Control in Advanced Urothelial Cancer

By MedXY 10/24/2025

Datroway combined with rilvegostomig demonstrates impressive tumor response and disease control in advanced urothelial carcinoma, heralding a new therapeutic option in first- and second-line settings.

Allergy & Immunology Oncology

More Than Half of Patients Experience Tumor Shrinkage! Clinical Data Unveiled for a Potential “First-in-Class” Therapy

By MedXY 10/24/2025

Marengo Therapeutics reports promising Phase 2 results for invikafusp alfa, showing significant tumor shrinkage and disease control in advanced solid tumors with high mutation burden or MSI-H/dMMR.

OB/GYN & Women's Health Oncology

Innovative Oral SERD Plus Everolimus Therapy Shows Superior Efficacy in Advanced ER+ HER2- Breast Cancer

By MedXY 10/24/2025

Roche announces positive phase 3 results of giredestrant plus everolimus, significantly reducing disease progression risk in ER+ HER2- advanced breast cancer patients post CDK4/6 inhibitor exposure, with favorable safety and promising survival trends.

news

创新口服SERD联合依维莫司疗法在晚期ER+ HER2-乳腺癌中显示优越疗效

By MedXY 10/24/2025

罗氏宣布giredestrant联合依维莫司的III期研究结果积极，显著降低之前接受过CDK4/6抑制剂治疗的ER+ HER2-晚期乳腺癌患者的疾病进展风险，且具有良好的安全性和生存趋势。

Oncology

Gedatolisib Demonstrates Promising Efficacy in Phase 3 VIKTORIA-1 Trial for HR+/HER2- Advanced Breast Cancer: NDA Submission Initiated

By MedXY 10/24/2025

Celcuity's phase 3 VIKTORIA-1 trial reveals that gedatolisib, a broad-spectrum PI3K/mTORC1/2 inhibitor, significantly improves progression-free survival in hormone receptor-positive, HER2-negative advanced breast cancer patients post CDK4/6 inhibitor therapy, prompting NDA rolling submission.

Nephrology news Rheumatology

FDA Approves Roche’s Obinutuzumab for Lupus Nephritis: Promising Advances in B-cell Targeted Therapy

By MedXY 10/24/2025

The FDA has approved Roche’s obinutuzumab for active lupus nephritis in adults, offering a twice-yearly dosing regimen that achieved nearly 50% complete renal remission in trials, marking a significant advancement in lupus nephritis management.

Hematology-Oncology news Ophthalmology

Advances in Targeted and Gene Therapies: Promising Data on KRAS G12D Inhibitors, DR5 Agonists, and Ocular Gene Therapy

By MedXY 10/24/2025

Recent clinical trials report encouraging tumor shrinkage with KRAS G12D inhibitor VS-7375, significant progression-free survival benefit in soft tissue sarcoma with ozekibart, and a novel gene therapy acquisition targeting wet AMD.

Dermatology news Plastic Surgery

Enhancing Surgical Outcomes: Hydrocolloid Dressings vs Petroleum Ointment for Scar Management

By MedXY 10/24/2025

This clinical trial compares the effectiveness and safety of hydrocolloid dressings versus petroleum ointment in post-surgical scar healing, emphasizing patient comfort and cosmetic outcomes.

Dermatology Hematology-Oncology news

T-Cell Receptor Clonotypes as Prognostic Markers in Cutaneous T-Cell Lymphoma: Insights from Next-Generation Sequencing

By MedXY 10/24/2025

This study identifies specific T-cell receptor clonotypes associated with aggressive subtypes and poorer survival in mycosis fungoides and Sézary syndrome, supporting TCR sequencing as a tool for refined risk stratification in cutaneous T-cell lymphoma.

news Oncology

Promising Dual-Antibody Therapy Petosemtamab Shows Remarkable Response in Metastatic Colorectal Cancer

By MedXY 10/24/2025

Mid-phase clinical data reveal petosemtamab combined with FOLFOX/FOLFIRI achieves up to 100% response in first-line left-sided metastatic colorectal cancer, with manageable safety profile and potential to address unmet needs in mCRC treatment.

OB/GYN & Women's Health

FDA Approves Bayer’s Lynkuet (Elinzanetant): A Novel Dual Neurokinin Receptor Antagonist for Menopausal Hot Flashes

By MedXY 10/24/2025

Bayer's Lynkuet (elinzanetant), a first-in-class dual neurokinin 1 and 3 receptor antagonist, has received FDA approval for treatment of moderate to severe menopausal vasomotor symptoms, demonstrating sustained efficacy and favorable safety in phase 3 trials.

Dermatology Pediatrics

Baricitinib Shows Promising Results in Restoring Hair Growth in Adolescents with Severe Alopecia Areata: Phase 3 BRAVE-AA-PEDS Trial

By MedXY 10/24/2025

The phase 3 BRAVE-AA-PEDS trial demonstrates that baricitinib, a JAK inhibitor, significantly restores scalp, eyebrow, and eyelash hair in adolescents with severe alopecia areata, achieving up to 80% hair regrowth in recent-onset cases after one year of treatment.

Cardiology news Public Health

Warm and Cold Risks: How Temperature Variations Impact Mortality in Swedish Heart Failure Patients

By MedXY 10/24/2025

This study reveals that both low and high ambient temperatures significantly increase mortality risk among Swedish heart failure patients, highlighting the need for climate adaptation strategies in high-latitude regions.

news Psychiatry

Evaluating Pramipexole as Adjunct Therapy in Treatment-Resistant Bipolar Depression: Insights from the PAX-BD Trial

By MedXY 10/24/2025

The PAX-BD trial assessed pramipexole addition to mood stabilisers in treatment-resistant bipolar depression, revealing some mood and psychosocial benefits but no significant primary outcome improvement, highlighting the need for further research.

news Psychiatry

Evaluating Serial Ketamine Infusions as Adjuncts in Inpatient Depression Care: Insights from the KARMA-Dep 2 Trial

By MedXY 10/24/2025

The KARMA-Dep 2 trial reveals that serial ketamine infusions do not significantly outperform midazolam in reducing depressive symptoms among inpatients receiving usual psychiatric care, challenging assumptions about ketamine’s long-term antidepressant benefits in this setting.

Pediatrics Psychiatry Public Health

Silent Long-Term Harm: How Prenatal Lead Exposure Shapes Adult Mental Health

By MedXY 10/24/2025

This article explores the link between prenatal and early postnatal lead exposure and adult anxiety and depression, emphasizing critical exposure windows and long-term mental health implications.

Dermatology General Surgery Oncology

Refining Sentinel Lymph Node Biopsy Decisions in Melanoma: Insights from the MERLIN_001 Gene Expression Profiling Study

By MedXY 10/24/2025

The MERLIN_001 study validates a combined clinicopathological and gene expression profile test that accurately predicts sentinel lymph node metastasis risk in patients with cutaneous melanoma, potentially guiding safer, more personalized surgical decisions.

news

新诊断的儿童免疫性血小板减少症中使用艾曲波帕：早期治疗策略的突破

By MedXY 10/24/2025

这项随机试验表明，艾曲波帕显著改善了新诊断为ITP的儿童的持续血小板反应，提供了一种潜在的早期干预选择。

Hematology-Oncology news Pediatrics

Eltrombopag in Newly Diagnosed Pediatric Immune Thrombocytopenia: A Breakthrough in Early Treatment Strategy

By MedXY 10/24/2025

This randomized trial demonstrates that eltrombopag significantly improves sustained platelet response in children with newly diagnosed ITP, offering a potential early intervention option.

From Discovery to Breakthroughs: How Multiple Myeloma Survival Has Doubled in 20 Years

Breakthrough ADC-Based Combination Therapy Achieves Over 95% Disease Control in Advanced Urothelial Cancer

More Than Half of Patients Experience Tumor Shrinkage! Clinical Data Unveiled for a Potential “First-in-Class” Therapy

Innovative Oral SERD Plus Everolimus Therapy Shows Superior Efficacy in Advanced ER+ HER2- Breast Cancer

创新口服SERD联合依维莫司疗法在晚期ER+ HER2-乳腺癌中显示优越疗效

Gedatolisib Demonstrates Promising Efficacy in Phase 3 VIKTORIA-1 Trial for HR+/HER2- Advanced Breast Cancer: NDA Submission Initiated

FDA Approves Roche’s Obinutuzumab for Lupus Nephritis: Promising Advances in B-cell Targeted Therapy

Advances in Targeted and Gene Therapies: Promising Data on KRAS G12D Inhibitors, DR5 Agonists, and Ocular Gene Therapy

Enhancing Surgical Outcomes: Hydrocolloid Dressings vs Petroleum Ointment for Scar Management

T-Cell Receptor Clonotypes as Prognostic Markers in Cutaneous T-Cell Lymphoma: Insights from Next-Generation Sequencing

Promising Dual-Antibody Therapy Petosemtamab Shows Remarkable Response in Metastatic Colorectal Cancer

FDA Approves Bayer’s Lynkuet (Elinzanetant): A Novel Dual Neurokinin Receptor Antagonist for Menopausal Hot Flashes

Baricitinib Shows Promising Results in Restoring Hair Growth in Adolescents with Severe Alopecia Areata: Phase 3 BRAVE-AA-PEDS Trial

Warm and Cold Risks: How Temperature Variations Impact Mortality in Swedish Heart Failure Patients

Evaluating Pramipexole as Adjunct Therapy in Treatment-Resistant Bipolar Depression: Insights from the PAX-BD Trial

Evaluating Serial Ketamine Infusions as Adjuncts in Inpatient Depression Care: Insights from the KARMA-Dep 2 Trial

Silent Long-Term Harm: How Prenatal Lead Exposure Shapes Adult Mental Health

Refining Sentinel Lymph Node Biopsy Decisions in Melanoma: Insights from the MERLIN_001 Gene Expression Profiling Study

新诊断的儿童免疫性血小板减少症中使用艾曲波帕：早期治疗策略的突破

Eltrombopag in Newly Diagnosed Pediatric Immune Thrombocytopenia: A Breakthrough in Early Treatment Strategy

Long-Term Success of Combined Myectomy and Secondary Mitral Chordal Cutting in Obstructive Hypertrophic Cardiomyopathy

Long-Term Efficacy and ctDNA Dynamics in Early-Stage ERBB2-Positive Breast Cancer Treated with Neoadjuvant Paclitaxel, Trastuzumab, and Pertuzumab: Insights from the DAPHNe Trial

Evaluating Telehealth Stepped Alcohol Treatment to Reduce Alcohol Use in Chronic Liver Disease: Insights from a 2026 Randomized Controlled Trial

Targeting NEK9 to Overcome Immunotherapy Resistance in Hepatocellular Carcinoma by Reprogramming the Tumor Microenvironment